FDA
-
-
-
-
-
-
-
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
-
-
-
-
-
-
-
Lipocine completes patient enrollment in phase 3 postpartum depression trial
-
-
-
-
-
-
-
Lipocine reaches 80% enrollment in postpartum depression drug trial
-
-
-
-
-
-
-
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
-
-
-
-
-
-
-
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
-
-
-
-
-
-
-
Lipocine (LPCN) Announces License and Supply Agreement for TLANDO in Brazil
-
-
-
-
-
-
-
Lipocine (LPCN) Granted FDA Fast Track Designation for LPCN 1148
-
330,719 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

